Selegiline: Difference between revisions

This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Selegiline" – news · newspapers · books · scholar · JSTOR (August 2006) (Learn how and when to remove this message)

Selegiline

Clinical data
Pregnancy category	C (US)
Routes of administration	Oral, transdermally
ATC code	N04BD01 (WHO)
Legal status
Legal status	prescription only (unscheduled) (US)
Pharmacokinetic data
Protein binding	> 99.5%
Elimination half-life	2 hours
Identifiers
IUPAC name N-methyl-N-(1-methyl-2-phenyl-ethyl)-prop-2-yn-1-amine
CAS Number	14611-51-9 [14611-52-0] (HCl), [2079-54-1] (deprenyl.HCl), [4530-70-5] ((+-)-isomer), [1205-70-5] ((+-)-isomer, HCl), [2323-36-6] (cpd w/o isomeric designation; deprenyl), [4528-51-2] ((S)-isomer), [4528-52-3] ((S)-isomer, HCl)
PubChem CID	26757
DrugBank	APRD00525
CompTox Dashboard (EPA)	DTXSID6023575
ECHA InfoCard	100.109.269
Chemical and physical data
Formula	C13H17N
Molar mass	187.281 g/mol

Selegiline (l-deprenyl, Eldepryl® or Anipryl® [veterinary]) is a drug used for the treatment of early-stage Parkinson's disease and senile dementia. In normal clinical doses it is a selective MAO-B inhibitor, however in larger doses (>20 mg in a typical adult) it loses its specificity and also inhibits MAO-A. Dietary restrictions are common for MAOI treatments, however, since Selegiline is selective for MAO-B, special dietary restrictions for lower doses have been found to be unnecessary.^[1] The drug was researched by Joseph Knoll.

It is sometimes used off-label to treat narcolepsy and as a nootropic, as well as for its purported life-extending effects. It is also reported to positively affect libido, particularly in older males. As of February 28, 2006, Selegiline has also been approved by the Food and Drug Administration (FDA) to treat major depression using a transdermal patch (Emsam Patch). Selegiline is also used (at extremely high dosages relative to humans) in veterinary medicine to treat the symptoms of Cushing's disease and so-called "cognitive dysfunction" in dogs. As of June 26, 2006, a Selegiline transdermal patch is being tested for its effectiveness in treating ADHD (Source:Pharma.org).

<a href="http://pendant.php5.cz/diamond/neil-diamond-sweet-caroline-lyric.html">neil diamond sweet caroline lyric</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-sweet-caroline.html">neil diamond sweet caroline</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-t-shirt.html">neil diamond t shirt</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-tab.html">neil diamond tab</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-the-christmas-special.html">neil diamond the christmas special</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-the-jazz-singer.html">neil diamond the jazz singer</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-ticket.html">neil diamond ticket</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-tour-date.html">neil diamond tour date</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-tour.html">neil diamond tour</a>
<a href="http://pendant.php5.cz/diamond/neil-diamond-video.html">neil diamond video</a>

Possibly due to the structural similarity to illegal stimulants, selegiline has been classified as a controlled substance in Japan and thus can only be obtained with a prescription or special government license.

February 28, 2006 - The Food and Drug Administration approved Emsam (selegiline), the first skin (transdermal) patch for use in treating major depression. The once a day patch works by delivering selegiline, a monoamine oxidase inhibitor or MAOI, through the skin and into the bloodstream. At its lowest strength, Emsam can be used without the dietary restrictions that are needed for all oral MAO inhibitors that are approved for treating major depression. It comes in three sizes that deliver 6, 9, or 12 mg of selegiline per 24 hours. The patch is a matrix containing three layers consisting of a backing, and adhesive drug layer, and a release liner that is placed against the skin. EMSAM was developed by Somerset Pharmaceuticals, Inc. In December 2004, Bristol-Myers Squibb and Somerset entered into an agreement that provides Bristol-Myers Squibb with distribution rights to market EMSAM after approval in the United States.

<a href="http://pendant.php5.cz/pendant/diamond-necklace-necklace-pendant.html">diamond necklace necklace pendant</a>
<a href="http://pendant.php5.cz/pendant/diamond-palm-tree-pendant.html">diamond palm tree pendant</a>
<a href="http://pendant.php5.cz/pendant/diamond-peace-pendant.html">diamond peace pendant</a>
<a href="http://pendant.php5.cz/pendant/diamond-peace-sign-pendant.html">diamond peace sign pendant</a>
<a href="http://pendant.php5.cz/pendant/diamond-pearl-pendant-tahitian.html">diamond pearl pendant tahitian</a>
<a href="http://pendant.php5.cz/pendant/diamond-pearl-pendant.html">diamond pearl pendant</a>
<a href="http://pendant.php5.cz/pendant/diamond-pendant-necklace.html">diamond pendant necklace</a>
<a href="http://pendant.php5.cz/pendant/diamond-pendant-setting.html">diamond pendant setting</a>
<a href="http://pendant.php5.cz/pendant/diamond-platinum-pendant.html">diamond platinum pendant</a>
<a href="http://pendant.php5.cz/pendant/diamond-sapphire-pendant.html">diamond sapphire pendant</a>

• Collection of Research Abstracts on Deprenyl
• Deprenyl Improves Learning And Memory
• Deprenyl (Selegiline) Can Slow Parkinson's Disease Safely According to the British Medical Journal
• FDA Approves Emsam (Selegiline) as First Drug Patch for Depression